Business Model
Our accelerator business model is to accelerate each organ-specific innovation and corresponding startup through first-in-man studies and then seek out a strategic partner.
The accelerator generally owns 5 to 20% seed-stage equity in any startup that it helped launch and support substantially. People investing in the early stage startups usually will invest 2:1 via the accelerator into the startups. Example – If they invest $30,000 in Leonhardt’s Launchpads Pittsburgh they will receive $30,000 worth of accelerator shares and a warrant to acquire at no additional charge $30,000 worth of shares of any of the startups being accelerated in Pittsburgh. They have until Dec. 31st of the year they invested to allocate their warrants giving time to monitor progress of each and to get to know each development and research team better. The startups generally start out at valuations $2.3 to $5 million at $1 per share and increase in value milestone by milestone with a focus on these items…
1. Filing patent protection.
2. Licensing key patents.
3. Gathering positive supporting data from lab, small animal, large animal and eventually first in man studies.
4. Gaining opinion leader endorsements – this comes from a commitment to educational meetings, seminars and publishing.
5. Gaining positive press, peer-reviewed publications and presentations at key meetings.
6. Research and commercialization partnerships.
The reach goal is to increase their valuations to about $90 to $900 million following clinical study results after 5 years while minimizing dilution of early contributors stakes.
Our accelerator focuses on bioelectric, biologics and endovascular organ regeneration and recovery technologies in these areas…
Heart & Cardiovascular
Cosmetic & Personal Care
Cancer
Brain
Major Organ Regeneration
After completing first in man studies we seek to secure an organ focused strategic partners to finance and lead the early stage development to full commercialization. We generally seek to secure a 3% royalty on net sales from our strategic buyer/partner in addition to an upfront and milestone payments.
Howard Leonhardt the founder of Leonhardt’s Launchpads has these issued patents.
The accelerator has licensed numerous patents from inventor Eleanor Schuler and her succeeding companies
The accelerator has licensed numerous patents from inventor Dr. Morteza Gharib of The California Institute of Technology Caltech
Our accelerator focuses on bioelectric, biologics and endovascular organ regeneration and recovery technologies in these areas…
OUR PRODUCTS
